Navigation Links
Unigene Restates Policy on Analyst Reports
Date:3/13/2008

FAIRFIELD, New Jersey, March 13 /PRNewswire-FirstCall/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it did not issue, authorize or approve the press release titled "Stonegate Report About Unigene Laboratories Inc.", which was released yesterday. Pursuant to the Company's policies and procedures, Unigene does not endorse, confirm, validate or otherwise comment on reports issued by analysts and unrelated third parties. Any opinions, estimates or forecasts regarding Unigene's performance made by analysts or other third parties are theirs alone and do not represent the opinions, estimates, forecasts or predictions of Unigene or its management.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(r), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(r) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973)-882-0860 or visit http://www.unigene.com. For information about Fortical, visit http://www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

Contact:

Warren P. Levy

President and CEO

Unigene Laboratories, Inc.

110 Little Falls Road

Fairfield, NJ 07004

Tel.: +1-(973)-882-0860

Fax: +1-(973)-227-6088

E-Mail: wlevy@unigene.com


'/>"/>
SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stonegate Report About Unigene Laboratories Inc.
2. U.S. Preventive Medicine National Policy Advisor Gov. Tommy Thompson to Propose Prevention is the Solution at UBS Global Health Services Conference
3. DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum
4. Bioscience Group Warns Policymakers Against Complacency
5. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
6. Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
7. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
8. Medco to Webcast Annual Analyst Day Conference
9. Webcast Alert: Isis Pharmaceuticals Announces its Analyst & Investor Day
10. DURECT to Host Webcast in Conjunction with an Analysts Day on October 17
11. Nu Skin Enterprises to Hold 2007 Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... excited to announce a strategic partnership with McGill University . The partnership is ... to the market in order to help patients in pain. With the new agreement, ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... has leveraged recent innovations in biotechnology to help treat hormonal and stress related ... loss, Nutrafol® has captured the hearts of key opinion leaders in the medical ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... announced the addition of Dr. Nancy Gillett to its Board of Directors. Dr. ... she served as Corporate Executive Vice President and Chief Scientific Officer. A board-certified ...
(Date:5/3/2016)... , ... May 03, 2016 , ... According to world ... for definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery or ... would be made. , New technology has enabled doctors to administer higher doses ...
Breaking Biology Technology:
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
Breaking Biology News(10 mins):